heart failure
Coverage of heart failure in the Nexus archive.
- 14 Questions to Ask Before Leaving the Hospital to Avoid Readmission
The article discusses how 15% of U.S. hospital stays result in readmissions, citing a case where a patient named Charlotte was readmitted due to an incorrect medication dose. It emphasizes asking critical questions before discharge to avoid readmissions, reduce healthcare costs, and prevent complications like hospital-acquired infections.
- Coffee may protect your heart but energy drinks could harm it
A new American Heart Association review suggests that up to 400 milligrams of caffeine daily, roughly three to five cups of coffee, is generally safe and may reduce risks of heart disease, stroke, and Type 2 diabetes. However, highly concentrated energy drinks and caffeine shots can increase blood pressure and cause irregular heart rhythms.
- Up to 5 cups of coffee per day may potentially lower heart disease risk, doctors say
Drinking up to five cups of coffee daily is considered safe for most adults, with regular consumption potentially lowering risks of stroke, diabetes, and heart failure.
- Up to 5 cups of coffee per day may potentially lower heart disease risk, doctors say
Drinking up to five cups of coffee daily is safe for most adults, with regular consumption potentially linked to reduced risks of stroke, diabetes, heart failure, and heart disease.
- Up to 5 cups of coffee per day may potentially lower heart disease risk, doctors say
Drinking up to five cups of coffee daily is safe for most adults and may reduce risks of stroke, diabetes, and heart failure. Regular coffee consumption could potentially lower heart disease risk.
- Up to 5 cups of coffee per day may potentially lower heart disease risk, doctors say
Drinking up to five cups of coffee daily is considered safe for most adults and may reduce the risk of stroke, diabetes, and heart failure.
- New AI blood test predicts heart disease 15 years early
A new AI-powered blood test called CardiOmicScore, developed by the University of Hong Kong, predicts heart disease up to 15 years in advance by analyzing proteins and metabolites. It assesses risk for six cardiovascular diseases, including heart attack, stroke, heart failure, and atrial fibrillation, and differs from genetic risk scores by reflecting current health, lifestyle, and environmental factors.
- Medication used to treat heart failure recalled nationwide
Nearly 1 million bottles of a heart failure medication are being recalled nationwide due to potential contamination with a foreign substance, as reported in an FDA recall alert.
- Nearly 1 million bottles of medication used to treat heart failure recalled nationwide
A nationwide recall has been issued for nearly 1 million bottles of Corlanor (ivabradine) due to potential contamination with a foreign substance, according to PIX11 News. The medication is used to reduce hospitalization risk in heart failure patients.
- STAT+: What an abandoned heart failure trial says about ‘breakthrough’ devices that don’t reach patients
LivaNova's VITARIA vagus nerve stimulator for heart failure, designated a FDA breakthrough device, failed to meet trial success criteria after enrolling 500 patients. The FDA's breakthrough device program, aimed at accelerating innovative treatments, did not ensure the device's market success.
- STAT+: Cadence raises $100 million to automate chronic disease care with regulated AI
Cadence, a digital health company, raised $100 million in funding led by Spark Capital, valuing the company at $1.23 billion. The investment aims to expand Cadence's chronic disease management programs and automate clinician work with AI, despite scrutiny over its billing model from the federal health department's watchdog and insurers like UnitedHealthcare.
- I’m a 32-year-old heart failure survivor — don’t ignore these 5 symptoms
A 32-year-old heart failure survivor highlights the importance of recognizing symptoms, as nearly 6.7 million Americans over 20 live with heart failure, often unaware due to its silent symptoms.
- STAT+: Heart patch engineered from stem cells revved up weakened hearts
A small study reports that heart patches engineered from induced pluripotent stem cells (BioVAT) improved heart wall thickness and pumping ability in patients with weakened hearts. The patches aim to serve as a bridge to heart transplant or LVAD implantation, with a larger trial needed to assess durability and candidacy.
- Common heart drug taken by millions found useless — and possibly dangerous
A large international study found beta blockers, commonly prescribed after heart attacks, offer no benefit for patients with normal heart function and may increase risks for women. The findings challenge four decades of standard treatment practices.
- Founder of Japan’s 7-Eleven chain Toshifumi Suzuki dies aged 93
Toshifumi Suzuki, founder of Japan’s 7-Eleven chain and former chairman of Seven & i Holdings, died at 93 from heart failure. He was credited with the global success of 7-Eleven and known as the 'father of the convenience store' in Japan.
- Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk
An international review demonstrates that GLP-1 weight-loss drugs such as Ozempic significantly reduce the risk of heart attacks, strokes, heart failure, and premature death. Researchers indicate these medications could serve as a major therapeutic tool against cardiovascular disease beyond their current use for obesity and diabetes treatment.
- How low should blood pressure go? Science has the answer
New research indicates that maintaining systolic blood pressure below 120 mm Hg may offer greater heart health benefits, including reduced risks of heart attack, stroke, and heart failure, compared to higher targets. The findings are based on large datasets and simulation models.
- Engineered immunosuppressive dendritic cells protect against cardiac remodelling
A study published in Nature demonstrates that engineered immunosuppressive dendritic cells can protect against cardiac remodelling. Lesion-targeted immune modulation is identified as a feasible strategy to control cardiac fibrosis, with engineered dendritic cells emerging as a promising therapeutic platform for treating cardiac remodelling and heart failure.